|
|
News Breaks | | | | September 24, 2012 | | 08:32 EDT |  | COV | Covidien unit to acquire CNS Therapeutics for approximately $100M
Mallinckrodt, the Pharmaceuticals business of Covidien, announced a definitive agreement to acquire CNS Therapeutics, Inc., a privately held specialty pharmaceutical company focused on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain. Mallinckrodt will acquire all of the outstanding capital stock of CNS Therapeutics, based in St. Paul, MN, for approximately $100M. The transaction, subject to customary closing conditions, is expected to be completed during the fourth calendar quarter of 2012. CNS currently has one marketed product and a diverse pipeline of pain and spasticity products in development. Assuming a fourth calendar quarter 2012 closing, Covidien does not expect this transaction to have a material impact on its fiscal 2013 sales or EPS. | |
|
News For COV From The Last 14 Days Check below for free stories on COV the last two weeks. |
|
|
| May 22, 2013 | | 07:00 EDT | | COV | Covidien announces positive results from clinical trial on endoscopic therapy
 Subscribe for More Information | | | May 20, 2013 | | 08:05 EDT | | COV | Covidien receives FDA 510(k) clearance for Nellcor pulse oximetry motion claims
Subscribe for More Information | | | May 16, 2013 | | 07:28 EDT |  | COV | I/O Central to host a conference
Subscribe for More Information | | | May 10, 2013 | | 06:16 EDT |  | COV | Obesity surgery booming in India, Bloomberg reports
Subscribe for More Information | |
|
|
|
|
|
|
